US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adsouth Partners, Inc.

0.0006

+0.0000

Volume:- -

Turnover:- -

Market Cap:85.10K

PE:0.00

High:0.0006

Open:0.0006

Low:0.0006

Close:0.0006

Loading ...

Overview Company News Filings

Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results

OraSure Reports Fourth Quarter 2024 Financial Results

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Why Is Moderna Stock Trading Higher On Tuesday?

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

UPDATE 1-US agency declares California wildfires a public health emergency

Basilea provides portfolio update and outlook

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Press Release: Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera(R) (ceftobiprole) in the United States

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test

Press Release: MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASPR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASPR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASPR\",,,,,undefined,":{"symbol":"ASPR","market":"US","secType":"STK","nameCN":"Adsouth Partners, Inc.","latestPrice":0.0006,"timestamp":1743105600000,"preClose":0.0006,"halted":0,"volume":0,"delay":15,"floatShares":10442039,"shares":141830741,"eps":-0.656674,"marketStatus":"Post-Market Trading","change":0,"latestTime":"03-27 16:00:00 EDT Delay","open":0.0006,"high":0.0006,"low":0.0006,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.656674,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743120000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"PINK","adjPreClose":0.0006,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASPR\",,,,,undefined,":{"symbol":"ASPR","floatShares":10442039,"roa":"-21.86%","roe":"-292.97%","lyrEps":-0.262582,"shares":141830741,"dividePrice":0,"high":0.0006,"amplitude":0,"preClose":0.0006,"low":0.0006,"week52Low":0.0002,"pbRate":"-0.10","psRate":"0.01","week52High":0.0006,"institutionHeld":0,"latestPrice":0.0006,"eps":-0.656674,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.656674,"open":0.0006,"prevYearClose":0.0006,"prevWeekClose":0.0006,"prevMonthClose":0.0006,"prevQuarterClose":0.0006,"fiveDayClose":0.0006,"twentyDayClose":0.0006,"sixtyDayClose":0.0006},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASPR\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522907532","title":"Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522907532","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522907532?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:55","pubTimestamp":1743108900,"startTime":"0","endTime":"0","summary":"2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study  On Track for Regulatory Submission in US for DeepViewSystem  DALLAS, March  27, 2025  (GLOBE NE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/27/3051062/0/en/Spectral-AI-Announces-2024-Fourth-Quarter-and-Full-Year-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","ASPR"],"gpt_icon":0},{"id":"2514410660","title":"OraSure Reports Fourth Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514410660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514410660?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:05","pubTimestamp":1740517500,"startTime":"0","endTime":"0","summary":"BETHLEHEM, Pa., Feb.  25, 2025  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3032436/11732/en/OraSure-Reports-Fourth-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4198","BK4139","HHS","BK4585","NG","BK4535","BK4017","BK4588","BK4551","BK4009","OSUR","ASPR","BNTX","BK4548"],"gpt_icon":0},{"id":"2508458639","title":"RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2508458639","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508458639?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:00","pubTimestamp":1738670400,"startTime":"0","endTime":"0","summary":"The 80-patientplacebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer , testing the potentially enhancing effect of opaganib in patients with a poor prognosis. The study is being financially supported by Bayer  and the Ramsay Hospital Research Foundation, and will be led by Professor Lisa Horvath from Chris O'Brien Lifehouse and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group . The study will utilize a companion lipid biomarker test  to select mCRPC patients who have a poor prognosis due to standard of care treatment and who may benefit from an opaganib + darolutamide combination treatment approach. Primary endpoint will be improved 12-month radiographic progression-free survival . Prostate cancer  is the second most diagnosed cancer in the world, with around 1.5 million new cases per year, causing almost 400,000 deaths. People with mC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RDHL","BK4007","BK4009","BK4209","BK4213","IE00B19Z4B17.USD","BK4192","AEIS","PFS","BK4211","IE00B66KJ199.SGD","ADT","IE00B7SZL793.SGD","IE0031619046.USD","BK4157","BK4195","PC","BK4165","ASPR","AR"],"gpt_icon":0},{"id":"2505523201","title":"Why Is Moderna Stock Trading Higher On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505523201","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505523201?lang=en_us&edition=fundamental","pubTime":"2025-01-22 01:08","pubTimestamp":1737479319,"startTime":"0","endTime":"0","summary":"Tuesday, Moderna Inc  stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.On Friday, Moderna announced ongoing support from the U.S. Department of Health and Human Services  to accelerate the development of mRNA-based pandemic influenza vaccines.The award was made through the Rapid Response Partnership Vehicle  Consortium with funding from the Biomedical Advanced Research and Development Authority , part of the HHS Administration for Strategic Preparedness and Response .Also Read: Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination. The project will support the late-stage development and licensure of pre-pandemic mRNA-based vaccines. The agreement will also expand clinical studies for up to five additional subtypes of pandemic influenza.In 2023, Moderna commenced a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine  in healthy adults 18 years and older","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-moderna-stock-trading-higher-170839302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASPR","BK4585","MRNA","BK4139","BK4534","BK4588","BK4501","BK4551","BK4009","HHS","BK4568","BK4532","BK4548","BK4533"],"gpt_icon":1},{"id":"2503669705","title":"Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503669705","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503669705?lang=en_us&edition=fundamental","pubTime":"2025-01-14 08:55","pubTimestamp":1736816100,"startTime":"0","endTime":"0","summary":"Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3008969/25416/en/Vaxart-Announces-Favorable-DSMB-Review-of-Sentinel-Cohort-from-COVID-19-Phase-2b-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","HHS","BK4139","BK4585","BK4535","BK4588","BK4551","BK4009","ASPR","BNTX","BK4548"],"gpt_icon":0},{"id":"2502816017","title":"UPDATE 1-US agency declares California wildfires a public health emergency","url":"https://stock-news.laohu8.com/highlight/detail?id=2502816017","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502816017?lang=en_us&edition=fundamental","pubTime":"2025-01-11 03:31","pubTimestamp":1736537503,"startTime":"0","endTime":"0","summary":"(Adds background in paragraphs 2,5 and details throughout)      Jan 10 (Reuters) - The U.S. Department of Health and Human Services (HHS) on Friday declared a public health emergency for California to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","LU2346227817.USD","HHS","LU2637428348.USD","BK4208","ASPR","CMS","LU1894683264.USD","BK4588","BK4585","BK4009"],"gpt_icon":0},{"id":"2501790008","title":"Basilea provides portfolio update and outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2501790008","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501790008?lang=en_us&edition=fundamental","pubTime":"2025-01-08 14:15","pubTimestamp":1736316900,"startTime":"0","endTime":"0","summary":"Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones.Maintaining its strong momentum, the commercial performance of Cresemba triggered several milestone payments to Basilea in 2024. By year-end 2024, Cresemba was marketed in more than 70 countries, including the United States , most EU member states, China and Japan. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September 2024 amounted to USD533million, a 20 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1. In September, Zevtera has been approved for New-Technology Add-On Payment  in the US, which will provide hospitals an incremental payment in addition to stand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/basilea-provides-portfolio-outlook-061500693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMS","BK4208","MAT","ASPR","LU2637428348.USD","LU1894683264.USD","BK4009","BK4585","NTAP","BK4139","LU0203347892.USD","SG9999001440.SGD","LU2346227817.USD","BK4588","BK4190","BPMUF","LU1894683348.USD","HHS","LU0203345920.USD","BK4170"],"gpt_icon":0},{"id":"2491693212","title":"Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693212","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693212?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:00","pubTimestamp":1734354000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Dec.  16, 2024  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Adminis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997495/33240/en/Emergent-BioSolutions-Receives-50-Million-Contract-Option-from-BARDA-to-Procure-Doses-of-CYFENDUS-Anthrax-Vaccine-Adsorbed-Adjuvanted.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4581","LU1894683264.USD","LU1244550221.USD","BK4566","LU1244550577.SGD","IE00B3T34201.USD","BK4533","BK4534","LU0234572021.USD","LU0098860793.USD","BK4588","BK4504","ASPR","BK4009","BK4583","BK4177","LU1162221912.USD","PEP","EBS","LU1929549753.HKD","LU1894683348.USD","LU0320765646.SGD","LU1244550494.USD","BK4550"],"gpt_icon":0},{"id":"2491634798","title":"Press Release: Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera(R) (ceftobiprole) in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2491634798","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491634798?lang=en_us&edition=fundamental","pubTime":"2024-12-16 14:15","pubTimestamp":1734329700,"startTime":"0","endTime":"0","summary":"Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera  in the United States. Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. , for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera  in the United States . Innoviva Specialty Therapeutics is a US-based biopharmaceutical company with an established hospital sales force and a core competence in commercializing anti-infective medicines.Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","HHS","BK4009","LENZ","UBCP","BK4139","ASPR","BK4211","BK4007","BK4232","INVA"],"gpt_icon":0},{"id":"2490013530","title":"Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2490013530","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490013530?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832000,"startTime":"0","endTime":"0","summary":"Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident. There are currently no known approved therapies for gastrointestinal acute radiation syndrome . Positive results from new in vivo studies of opaganib as a treatment for GI-ARS, undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program product pipeline development contract, further confirm opaganib's protective activity. \"There are currently no known approved therapies for GI-ARS. Growing geopolitical tensions and Homeland Security concerns call for development of new potential therapies that can be quickly and easily deployed in the event of a mass casualty nuclear or radiological incident,\" said Gilead Raday, RedHill's Chief Operating Officer and Head of Research and Development. \"Opaganib, as an oral, small molecule pill that is highly s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/radioprotective-activity-redhills-opaganib-gi-120000463.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/radioprotective-activity-redhills-opaganib-gi-120000463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","BK4585","BNTX","BK4551","BK4007","IE00B19Z4B17.USD","BK4535","BK4009","BK4548","BK4568","BK4139","IE00B7SZL793.SGD","ASPR","BK4157","BK4588","IE00B66KJ199.SGD","RDHL","AEIS"],"gpt_icon":0},{"id":"2488985182","title":"Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2488985182","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488985182?lang=en_us&edition=fundamental","pubTime":"2024-12-03 05:01","pubTimestamp":1733173260,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Dec.  02, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vax","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/02/2990122/25416/en/Vaxart-Completes-Enrollment-of-Sentinel-Cohort-in-Phase-2b-Study-Evaluating-Its-COVID-19-Oral-Pill-Vaccine-Candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BNTX","BK4535","BK4551","HHS","BK4009","BK4588","BK4548","BK4585","ASPR"],"gpt_icon":0},{"id":"2488767366","title":"OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2488767366","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488767366?lang=en_us&edition=fundamental","pubTime":"2024-12-02 20:05","pubTimestamp":1733141100,"startTime":"0","endTime":"0","summary":"BETHLEHEM, Pa., Dec.  02, 2024  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/02/2989666/11732/en/OraSure-Receives-Federal-Funding-for-Development-of-Marburg-Virus-Rapid-Antigen-Test.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4198","OSUR","BNTX","BK4548","BK4535","BK4568","BK4588","BK4139","ASPR","BK4585","HHS","BK4009"],"gpt_icon":0},{"id":"2479189082","title":"Press Release: MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2479189082","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479189082?lang=en_us&edition=fundamental","pubTime":"2024-10-31 21:15","pubTimestamp":1730380500,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct. 31, 2024  -- MiNK Therapeutics , a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T  cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome , emerging threats, and immune related diseases.MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T  cell therapies to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASPR","LENZ","INKT","ARDS","HHS","BK4139","BK4009"],"gpt_icon":1},{"id":"2477333392","title":"Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2477333392","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477333392?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598400,"startTime":"0","endTime":"0","summary":"Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent A ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/22/2966887/0/en/Grifols-Partners-with-BARDA-for-Proof-of-Concept-Testing-of-Ocular-Immunoglobulin-as-Treatment-for-Sulfur-Mustard-Induced-Eye-Injury.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PACI.U","HHS","GRFS","BK4139","ASPR","BK4009"],"gpt_icon":0},{"id":"2477382096","title":"RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2477382096","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477382096?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:00","pubTimestamp":1729594800,"startTime":"0","endTime":"0","summary":"The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA's Animal Rule pathway to approval. Used as a chemical weapon during World War I, phosgene, a toxic, colorless chemical, is today widely used in industrial processes for the manufacture of plastics and pesticides. The U.S. Environmental Protection Agency  identified 123 sites in the United States that could potentially expose millions of people to phosgene due to plant malfunction or bioterrorism[1]. Phosgene inhalation can be extremely dangerous, causing significant, even fatal, respiratory injury. No known approved antidote or reversal agent currently exists, and, if approved, opaganib may provide potential for stockpiling for emergency use in the event of a major public safety inciden","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-announces-collaboration-leading-u-110000807.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-announces-collaboration-leading-u-110000807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4009","BNTX","BK4007","BK4551","BK4588","RDHL","BK4548","BK4585","ARDS","ASPR","BK4535","BK4139","BK4568"],"gpt_icon":0},{"id":"2472785697","title":"GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat","url":"https://stock-news.laohu8.com/highlight/detail?id=2472785697","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472785697?lang=en_us&edition=fundamental","pubTime":"2024-10-03 20:00","pubTimestamp":1727956800,"startTime":"0","endTime":"0","summary":"The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs. GigaGen’s recombinant polyclonals are part of Grifols’ robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals. GigaGen recently received clearance from the U.S. Food and Drug Administration  for its Investigational New Drug  application to initiate a Phase 1 clinical trial to evaluate the company’s first recombinant polyclonal antibody therapeutic for the treatment of hepatitis B virus  infection, GIGA-2339. The company anticipates initiating the trial in Q4 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/a32Ols.dE4OB9GbHQEhhOg--~B/aD0yMjQ7dz00OTk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9efe0e5200e5a72674029ce90622d1cb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/a32Ols.dE4OB9GbHQEhhOg--~B/aD0yMjQ7dz00OTk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9efe0e5200e5a72674029ce90622d1cb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gigagen-awarded-u-barda-contract-120000350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4009","GRFS","DOD","HHS","ASPR"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":19}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASPR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASPR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASPR\",market:\"US\",delay:false,,,undefined,":{}}}